Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP000164) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
DART anti-cadherin/CD3 PF-06671008
|
|||||
| Synonyms |
PF-06671008
|
|||||
| Thermal Denaturation TEMP | >68 ℃ | |||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Expression System | Chinese hamster ovary cells | |||||
| Selection Method | Phage display | |||||
| Highest Status | Research | |||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS028 | [1] | ||||
| Scaffold Name | DART | |||||
| Scaffold Class | Antibody fragment | |||||
| Fold Type | Beta-Sheets + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| T-cell surface glycoprotein CD3 | Inhibitor | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Kd: 0.18 nM | Pfrizer; MacroGenics | [1] | |
| Cadherin-3 | Inhibitor | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Kd: 0.18 nM | Pfrizer; MacroGenics | [1] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT02659631 | Click to show the Detail | |||||
| Indication | Advanced Solid Tumor | |||||
| Phase | Phase I | |||||
| Title | A Phase I DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS | |||||
| Status | Terminated | |||||
| Sponsor | Pfizer | |||||